Clinical trials
Newly Diagnosed clinical trials
Below are recruiting newly diagnosed clinical trials, each written for real people, not researchers. We’re tracking 393 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05723471Recruiting
Physical activity program for newly diagnosed cancer patients
This trial studies whether a structured exercise (physical activity) program started soon after a new cancer diagnosis is safe and helpful. You may benefit if you can safely do activity and meet key health measures.
Nancy, FranceAges 18 years+ - NCT05739981RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05768919RecruitingPhase 1/Phase 2
Liposomal curcumin with radiation and temozolomide for new brain cancer
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05781152RecruitingPhase 4
Testing how new Crohn’s imaging and scopes predict outcomes
This study follows children newly diagnosed with Crohn’s disease to see how results from scans and endoscopy (camera scope) relate to outcomes over the first year. It may help doctors choose better early treatment plans and monitor children more effectively.
Phoenix, ArizonaAges 6–17 - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Phoenix, ArizonaAges 1 month–21 years - NCT05866432RecruitingPhase 2
Dato-DXd for triple-negative breast cancer brain metastases
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
Vienna, State of ViennaAges 18–100 - NCT05879250RecruitingPhase 2
WP1066 plus radiation for newly diagnosed glioblastoma
This trial tests whether the study drug WP1066 combined with radiation can better control newly diagnosed glioblastoma, a fast-growing brain tumor. It also aims to check safety and how well tumors respond by using brain scans.
Chicago, IllinoisAges 18 years+ - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Birmingham, AlabamaAges 18 years+ - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Orange, CaliforniaAges 18–75 - NCT05900882RecruitingPhase 2
Test drug for newly diagnosed myeloma with tumors outside bone
This Phase 2 trial studies a treatment called SVRd in people newly diagnosed with multiple myeloma that has spread to areas outside the bone (called extramedullary disease). It aims to see how well the treatment works and whether it is safe for this specific group.
Changzhou, JiangsuAges 18–75 - NCT05904106RecruitingPhase 2
Venetoclax plus azacitidine versus stronger chemotherapy for AML
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
Essen, North Rhine-WestphaliaAges 18–70 - NCT05907057RecruitingPhase 3
Ivosidenib plus azacitidine for newly diagnosed AML
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
ViennaAges 18 years+ - NCT05914662RecruitingPhase 2
Zanubrutinib plus BR for newly diagnosed symptomatic WM
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05939180RecruitingPhase 2/Phase 3
Compare two induction treatments for newly diagnosed high-risk AML
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
Suzhou, JiangsuAges 18–64 - NCT05940493RecruitingPhase 2
Abemaciclib for newly diagnosed grade 3 meningioma
This trial tests abemaciclib, a targeted medicine, to see if it can help people with newly diagnosed grade 3 meningioma after standard radiation treatment. It may help by slowing tumor growth or improving outcomes after initial therapy.
Phoenix, ArizonaAges 18 years+ - NCT05952453RecruitingPhase 2
New ovarian cancer treatment with chemo plus maintenance medicines
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT05998642RecruitingPhase 2
Ibrutinib combo for newly diagnosed brain lymphoma
This trial tests a combination of ibrutinib, methotrexate, and rituximab for people with newly diagnosed primary CNS lymphoma who cannot have a stem cell transplant. It aims to see if this drug combination can effectively treat the disease.
Calgary, AlbertaAges 18 years+ - NCT06005870RecruitingPhase 2
Zanubrutinib with R-CHOP for newly diagnosed p53-positive DLBCL
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06012695RecruitingPhase 1/Phase 2
Study of an oral drug for solid tumors or glioblastoma
This trial tests an oral drug called NBM-BMX for people with advanced solid tumors that have not responded to other treatments, or for people with newly diagnosed glioblastoma (a type of brain cancer). The study aims to see if the drug is safe and effective.
Kaohsiung CityAges 18 years+ - NCT06014489RecruitingPhase 2
Venetoclax with azacitidine for untreated AML
This trial tests a combination of venetoclax and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) who cannot have or choose not to have intensive chemotherapy. The goal is to see if adding a drug called cobicistat helps the treatment work better.
AmersfoortAges 18 years+ - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Goodyear, ArizonaAges 18 years+ - NCT06023641RecruitingPhase 2
Liposomal irinotecan for children with rhabdomyosarcoma
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
Palo Alto, CaliforniaAges Up to 22 years - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Birmingham, AlabamaAges 18 years+
Hear when a new Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for newly diagnosed?
- Yes. Clin2 currently lists 393 recruiting newly diagnosed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a newly diagnosed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a newly diagnosed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.